Compare Dollar General Corp. (DG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Neurocrine Biosciences Inc — how do they compare? Dollar General Corp. trades at $123.9 (market cap $27.42B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Dollar General Corp. is the larger of the two by market cap, and Dollar General Corp. pays a 1.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DG | NBIX | |
|---|---|---|
Market Cap | $27.42B | $14.36B |
Volume | 2,291,517 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $185.50 |
52-Week Low | $95.94 | $123.10 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $41.60B | $14.37B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DG trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong profitability with a 19.69% ROE and has beaten earnings estimates for the last three quarters. Recent news highlights margin benefits from tariff refunds and expansion of delivery services through Instacart. Cash flow from operations improved to $3.0 billion in 2025, supporting financial stability.
The outlook is positive with a consensus price target of $137.27, implying over 12% upside. Risks include competitive pressures and potential consumer spending weakness. Analyst sentiment is bullish with 55.77% buy ratings, but net income margin compression from 7.01% in 2022 to 2.77% in 2025 warrants monitoring.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
